keyword
https://read.qxmd.com/read/38315832/outcomes-of-subsequent-anti-lymphoma-therapies-after-second-line-axicabtagene-ciloleucel-or-standard-of-care-in-zuma-7
#21
JOURNAL ARTICLE
Armin Ghobadi, Javier Munoz, Jason R Westin, Frederick L Locke, David B Miklos, Aaron P Rapoport, Miguel-Angel Perales, Patrick M Reagan, Joseph P McGuirk, Caron A Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O Oluwole
In ZUMA-7 (NCT03391466), axicabtagene ciloleucel (axi-cel) significantly improved outcomes versus second-line (2L) standard of care (SOC) for adults with relapsed/refractory large B-cell lymphoma (LBCL). The optimal management of patients after disease progression or lack of response to 2L therapy remains unclear. Here, we report outcomes among patients who received subsequent anti-lymphoma therapy per investigator discretion separately by their randomized 2L arm in ZUMA-7. Progression-free survival (PFS) and overall survival (OS) were calculated from 3L therapy initiation by randomized 2L arm...
February 5, 2024: Blood Advances
https://read.qxmd.com/read/38314662/utility-of-allogeneic-stem-cell-transplantation-for-adult-ph-all-with-complete-molecular-remission
#22
JOURNAL ARTICLE
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Itaru Matsumura, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Yasushi Miyazaki, Hitoshi Kiyoi
This study aimed to investigate the usefulness of allogeneic stem cell transplantation (allo-SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in the first complete remission (CR1) with complete molecular remission (CMR). We compared the outcomes between Ph+ALL patients who did or did not undergo allo-SCT in CR1. We included patients enrolled in the prospective clinical studies in the tyrosine kinase inhibitor era conducted by the Japan Adult Leukemia Study Group, who achieved CMR within 3 months...
February 5, 2024: American Journal of Hematology
https://read.qxmd.com/read/38303054/efficacy-and-safety-of-stem-cell-therapy-for-crohn-s-disease-a-meta-analysis-of-randomized-controlled-trials
#23
REVIEW
Yunfeng Qiu, Changfeng Li, Shihou Sheng
PURPOSE: Small-scale clinical trials have provided evidence suggesting the effectiveness of stem-cell therapy (SCT) for patients diagnosed with Crohn's disease (CD). The objective of the research was to systematically assess the effectiveness and safety of SCT for individuals diagnosed with CD through a comprehensive review and meta-analysis. METHODS: A search was conducted in Medline (PubMed), CENTER (Cochrane Library), and Embase (Ovid) to find randomized controlled trials (RCTs) that assessed the impact of SCT on the occurrence of clinical remission (CR) and severe adverse events (SAE) among patients diagnosed with CD...
February 2, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38295282/autophagy-prevents-graft-failure-during-murine-graft-versus-host-disease
#24
JOURNAL ARTICLE
Katie E Lineburg, Lucie Leveque-El Mouttie, Christopher R Hunter, Laeitia Le Texier, Crystal McGirr, Bianca Teal, Bruce R Blazar, Steven W Lane, Geoffrey R Hill, Jean-Pierre Levesque, Kelli P A MacDonald
Autophagy is an intracellular survival process that has established roles in the long-term survival and function of hematopoietic stem cells (HSC). We investigated the contribution of autophagy to HSC fitness during allogeneic transplantation and GVHD. We demonstrate in vitro that both TNF and IL-1β, major components of GVHD cytokine storm, synergistically promote autophagy in both HSC and their more mature hematopoietic progenitor cells (HPC). In vivo we demonstrate that autophagy is increased in donor HSC and HPC during GVHD...
January 31, 2024: Blood Advances
https://read.qxmd.com/read/38286692/protocol-for-a-comparative-cross-sectional-study-on-characterisation-of-auditory-impairment-in-sickle-cell-disease-and-sickle-cell-trait-and-its-impact-on-health-related-quality-of-life-in-nigeria
#25
JOURNAL ARTICLE
Titus S Ibekwe, Christine Rogers, Obiageli Nnodu, Lebogang Ramma
INTRODUCTION: Sickle cell disease (SCD) and sickle cell traits (SCT) are genetically inherited red blood cell disorders common among people of African descent. Nigeria has a high prevalence of SCD, with a prevalence of 2.28%-3% and SCT, 25%-30%. Poorly managed SCD and SCT can lead to sensorineural hearing loss and health-related quality of life (HRQoL) issues. This research aims to assess these possible complications of SCD and SCT in Nigeria. METHODS AND ANALYSIS: The study will use a comparative cross-sectional design at study power 80% to investigate the association between SCD/SCT, hearing impairment and HRQoL...
January 29, 2024: BMJ Open
https://read.qxmd.com/read/38267560/auto-hematopoietic-stem-cell-transplantation-or-chemotherapy-meta-analysis-of-clinical-choice-for-aml
#26
REVIEW
Songyu Ge, Jining Wang, Qin He, Jiaqi Zhu, Pai Liu, Hongtao Wang, Fan Zhang
For patients with acute myeloid leukemia (AML) who are not candidates for allogeneic stem cell transplantation (SCT) or do not have a human leukocyte antigen (HLA)-matched donor, it is unclear whether autologous SCT (ASCT) has a better prognosis after the first complete response (CR1) compared to further chemotherapy treatment. A meta-analysis evaluating ASCT compared to further chemotherapy for AML patients in CR1 was performed. The Medline, Embase, Cochrane Controlled Trials Registry, Cochrane Library, Web of Science, and National Knowledge Infrastructure of China databases were searched for relevant literature as of May 26, 2023...
January 25, 2024: Annals of Hematology
https://read.qxmd.com/read/38266155/incidence-and-risk-factors-of-early-onset-vod-sos-differ-in-younger-vs-older-adults-after-stem-cell-transplantation
#27
JOURNAL ARTICLE
Curtis Marcoux, Rima M Saliba, Whitney Wallis, Sajad J Khazal, Dristhi Ragoonanan, Gabriela Rondon, Priti Tewari, Uday R Popat, Betul Oran, Amanda L Olson, Qaiser Bashir, Muzaffar H Qazilbash, Amin Alousi, Chitra Hosing, Yago Nieto, Gheath Alatrash, David C Marin, Katayoun Rezvani, Issa F Khouri, Samer A Srour, Richard E Champlin, Elizabeth J Shpall, Partow Kebriaei
Veno-occlusive disease (VOD) is a rare but potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-SCT). While increasing awareness and modern transplant techniques have mitigated risk, the interaction of historic risk factors in the current era with post-transplant cyclophosphamide (PTCy) is unknown. We performed a retrospective single center analysis of adult patients 18 years or older undergoing allo-SCT (N=1561) using predominately PTCy as GVHD prophylaxis (72%)...
January 24, 2024: Blood Advances
https://read.qxmd.com/read/38255651/women-s-sexual-dysfunctions-following-stem-cell-transplant-and-the-impact-on-couple-relationship
#28
JOURNAL ARTICLE
Mihaela Plotogea, Anca Zgura, Claudia Mehedințu, Francesca Scurtu, Aida Petca, Valentin Nicolae Varlas, Roxana Georgiana Bors, Antoine Edu, Oana-Maria Ionescu, Mihaela Andreescu, Radu Nicolae Mateescu, Al Jashi Isam
Stem cell transplant proved its efficacy in increasing the survival rate among young patients diagnosed with hematological malignancies. A transplant conditioning regimen is particularly destructive on the genital system, often determining premature ovarian failure, accompanied by vulvovaginal atrophy and sexual dysfunctions. The aims of the present study were, first, to evaluate sexual dysfunctions among transplanted women, using clinical examination and the female sexual function index (FSFI), and second, to determine their impact on a couple's relationship...
December 25, 2023: Life
https://read.qxmd.com/read/38241244/prevalence-of-sickle-cell-trait-and-needs-assessment-for-uptake-of-sickle-cell-screening-among-secondary-school-students-in-kampala-city-uganda
#29
JOURNAL ARTICLE
Shamim Namukasa, Rose Maina, Sarah Nakaziba, Grace Among, Lydia Asasira, Posiano Mayambala, Joseph Atukwatse, Mary Namuguzi, Ahmed M Sarki
BACKGROUND: Sickle cell disease (SCD) is one of the most frequent and traumatizing genetic disease in Uganda, with the prevalence of the sickle cell trait (SCT) estimated at 13.3% leading to serious psycho-social and economic impact on the patients and their families. AIM: This study aimed to determine the burden of SCT and factors influencing the uptake of screening services among secondary school students in Uganda. METHODS: We used an analytical cross-sectional design with a multi-stage sampling approach...
2024: PloS One
https://read.qxmd.com/read/38227075/hla-haploidentical-t-cell-receptor-%C3%AE-%C3%AE-t-b-cell-depleted-stem-cell-transplantation-for-fanconi-anemia
#30
JOURNAL ARTICLE
Akihiro Iguchi, Toru Uchiyama, Kentaro Fujimori, Yoshihiro Gocho, Hirotoshi Sakaguchi, Takao Deguchi, Daisuke Tomizawa, Ken-Ichi Imadome, Masafumi Onodera, Kimikazu Matsumoto
HLA-haploidentical stem cell transplantation (haplo-SCT) using post-transplant high-dose cyclophosphamide (PT-CY) is an alternative choice when a suitable donors is unavailable. However, PT-CY is difficult in patients with Fanconi anemia (FA) due to their high vulnerability to alkylating agents. For FA, we prefer haplo-SCT by T-cell receptor αβT-cell and B-cell depletion (αβT/B-depleted haplo-SCT), which can reduce the risks of PT-CY-related complications and graft-versus-host disease (GVHD)...
January 16, 2024: International Journal of Hematology
https://read.qxmd.com/read/38207179/the-role-of-outpatient-physical-medicine-and-rehabilitation-in-a-multidisciplinary-prehabilitation-program-for-older-adults-before-allogeneic-hematopoietic-stem-cell-transplant
#31
JOURNAL ARTICLE
Jessica T Cheng, Obada Obaisi, Rajesh Yadav, Ekta Gupta, Jack B Fu, Eduardo Bruera, Alisha Collaco, Nicholas Szewcyzk, Uday Popat, An Ngo-Huang
INTRODUCTION: Physical rehabilitation is increasingly incorporated throughout the allogeneic hematopoietic stem cell transplant (allo-HSCT) journey for older adults. OBJECTIVE: This study aimed to describe physical medicine and rehabilitation (PM&R)-related diagnoses, exercise barriers, and management recommendations for older adults before allo-HSCT. DESIGN: Fifty PM&R consults as part of the Enhanced Recovery-Stem Cell Transplant (ER-SCT) multidisciplinary prehabilitation program at a comprehensive cancer center were retrospectively reviewed...
January 8, 2024: American Journal of Physical Medicine & Rehabilitation
https://read.qxmd.com/read/38201471/congenital-tumors-magnetic-resonance-imaging-findings-with-focus-on-rare-tumors
#32
JOURNAL ARTICLE
Piotr Kwasniewicz, Julia Wieczorek-Pastusiak, Anna Romaniuk-Doroszewska, Monika Bekiesinska-Figatowska
Congenital tumors are rare and, owing to this rarity, there is limited information on many of them. A total of 839 fetal and postnatal MRI studies performed in the first 3 months of life were retrospectively reviewed. They were performed with the use of 1.5 T scanners. Seventy-six tumors were diagnosed based on fetal MRI between 20 and 37 gestational weeks, and 27 were found after birth, from 1 day of age to 3 months of life. Teratomas were the most common tumors in our dataset, mainly in the sacrococcygeal region (SCT), followed by cardiac rhabdomyomas and subependymal giant cell astrocytomas (SEGA) associated with TSC, and neuroblastomas...
December 20, 2023: Cancers
https://read.qxmd.com/read/38197938/prophylactic-maintenance-with-venetoclax-azacitidine-after-reduced-intensity-conditioning-allo-transplant-for-high-risk-mds-and-aml
#33
JOURNAL ARTICLE
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S Cutler, Mahasweta Gooptu, Vincent T Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman M Shapiro, Daniel J DeAngelo, Richard M Stone, Denbaa Bat-Erdene, Jeremy Adam Ryan, Manuel E Contreras, Geoffrey Fell, Anthony Letai, Jerome Ritz, R Coleman Lindsley, Robert J Soiffer, Joseph H Antin
We conducted a phase 1 trial assessing safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine (Ven/Aza) in patients with high risk myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) undergoing reduced intensity allogeneic hematopoietic stem cell transplantation following venetoclax and FluBu2-conditioning (Ven/FluBu2 allo-SCT) with tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Among 27 patients who underwent Ven/FluBu2 allo-SCT (55.6% prior venetoclax exposure and 96% molecular measurable residual disease (MRD)-positive), 22 received maintenance therapy with azacitidine 36 mg/m2 intravenously on days 1-5 and venetoclax 400 mg by mouth on days 1-14 on one of two schedules (42-day cycles x 8 or 28-day cycles x 12)...
January 10, 2024: Blood Advances
https://read.qxmd.com/read/38197719/pre-transplant-glomerular-hyperfiltration-is-not-a-risk-factor-for-increased-renal-morbidity-and-mortality-in-pediatric-stem-cell-transplant-patients
#34
JOURNAL ARTICLE
Neil Sarkar, Kasiani C Myers, Adam Lane, Stella M Davies, Stefanie W Benoit
Low glomerular filtration rate (GFR) prior to stem cell transplant (SCT) is associated with increased morbidity and mortality. The implications of abnormally high GFRs, or glomerular hyperfiltration, prior to SCT are unknown. Twenty-two of 74 consecutive pediatric SCT patients over 2 years old at a single center were hyperfiltrating prior to SCT, median nuclear medicine GFR 154 mL/min/1.73 m2 [interquartile range: 146-170]. There was no association between hyperfiltration and any transplant demographics, nor between hyperfiltration and acute kidney injury (p = ...
April 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38195323/soho-state-of-the-art-updates-and-next-questions-next-questions-acute-lymphoblastic-leukemia
#35
REVIEW
Jayastu Senapati, Hagop Kantarjian, Fadi G Haddad, Nicholas J Short, Mary Alma Welch, Nitin Jain, Elias Jabbour
The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-Hyper-CVD) in combination with inotuzumab and blinatumomab has improved the 5-year OS rate to 50%...
January 8, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38194088/diagnostic-management-of-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-in-close-interaction-with-therapeutic-considerations
#36
JOURNAL ARTICLE
Evgenii Shumilov, Paolo Mazzeo, Susanne Ghandili, Axel Künstner, Sören Weidemann, Yara Banz, Philipp Ströbel, Matthias Pollak, Lina Kolloch, Helmut Beltraminelli, Andrea Kerkhoff, Jan-Henrik Mikesch, Christoph Schliemann, Detlef Haase, Gerald Wulf, Myriam Legros, Georg Lenz, Laurence Feldmeyer, Thomas Pabst, Hanno Witte, Niklas Gebauer, Ulrike Bacher
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare malignancy derived from plasmacytoid dendritic cells, can mimic both acute leukemia and aggressive T-cell lymphoma. Therapy of this highly aggressive hematological disease should be initiated as soon as possible, especially in light of novel targeted therapies that have become available. However, differential diagnosis of BPDCN remains challenging. This retrospective study aimed to highlight the challenges to timely diagnoses of BPDCN. We documented the diagnostic and clinical features of 43 BPDCN patients diagnosed at five academic hospitals from 2001-2022...
January 9, 2024: Annals of Hematology
https://read.qxmd.com/read/38184303/adoptive-transfer-of-cmv-specific-tcr-t-cells-for-the-treatment-of-cmv-infection-after-haploidentical-hematopoietic-stem-cell-transplantation
#37
JOURNAL ARTICLE
Chao Ma, Peng Chen, Jishan Du, Lu Wang, Ning Lu, Jiaojun Sun, Xu Qilong, Yu Wang, Liping Dou, Dai-Hong Liu
BACKGROUND: Cytomegalovirus (CMV) reactivation after unmanipulated haploidentical stem cell transplantation (SCT) frequently occurs, causing life-threatening morbidities and transplantation failure. Pre-emptive therapy upon the detection of CMV viremia using antiviral agents is currently the standard of care but it was associated with significant toxicity. The CMV antigen-specific cytotoxic T lymphocyte therapy was limited by the time-consuming manufacture process and relatively low success rate...
January 6, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38167647/ofatumumab-as-part-of-reduced-intensity-conditioning-in-high-risk-b-cell-lymphoma-patients-final-long-term-analysis-from-a-prospective-multicenter-phase-ii-trial
#38
JOURNAL ARTICLE
Mónica Cabrero, Lucia López-Corral, Isidro Jarque, Fátima de la Cruz-Vicente, Estefanía Pérez-López, David Valcárcel, Jaime Sanz, Ildefonso Espigado, Guillermo Ortí, Carmen Martín-Calvo, Javier de la Serna, Dolores Caballero
Curative potential of allogeneic transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (NHL) could be enhanced by the integration of Ofatumumab (OFA), a 2nd generation anti-CD20 moAb, due to an antitumor effect and a role over graft-versus-host disease (GVHD). In this phase II trial (NCT01613300), we investigated safety and effectiveness of OFA-based reduced intensity conditioning (RIC). High-risk B-cell NHL patients with chemorrefractory disease or post-autologous SCT relapse were eligible. OFA was added to a standard RIC regimen...
January 2, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38162948/covid-19-outcomes-in-patients-with-sickle-cell-disease-and-sickle-cell-trait-compared-with-individuals-without-sickle-cell-disease-or-trait-a-systematic-review-and-meta-analysis
#39
JOURNAL ARTICLE
Isabella Michelon, Maysa Vilbert, Isabella Silveira Pinheiro, Isabela Lino Costa, Cecilia Fernandes Lorea, Mathias Castonguay, Thai Hoa Tran, Stéphanie Forté
BACKGROUND: Clinical manifestations and severity of SARS-CoV-2 infection in individuals with sickle cell disease (SCD) and sickle cell trait (SCT) are not well understood yet. METHODS: We performed a systematic review and meta-analysis to assess COVID-19 outcomes in individuals with SCD or SCT compared to individuals without sickle cell disease or trait. An electronic search on PubMed, Embase, and Cochrane Library was performed on August 3, 2023. Two authors (IFM and ISP) independently screened (IFM and ISP) and extracted data (IFM and ILC) from included studies...
December 2023: EClinicalMedicine
https://read.qxmd.com/read/38152413/influence-of-invasive-aspergillosis-during-acute-leukaemia-treatment-on-survival-after-allogeneic-stem-cell-transplantation-a-prospective-study-of-the-ebmt-infectious-diseases-working-party
#40
JOURNAL ARTICLE
Olaf Penack, Gloria Tridello, Urpu Salmenniemi, Rodrigo Martino, Nina Khanna, Katia Perruccio, Franca Fagioli, Monika Richert-Przygonska, Hélène Labussière-Wallet, Johan Maertens, Charlotte Jubert, Mahmoud Aljurf, Herbert Pichler, Gergely Kriván, Desiree Kunadt, Marina Popova, Melissa Gabriel, Elisabetta Calore, Igor Wolfgang Blau, Fabio Benedetti, Maija Itäla-Remes, Elizabeth de Kort, Domenico Russo, Maura Faraci, Anne-Lise Ménard, Peter von dem Borne, Xavier Poiré, Akif Yesilipek, Jolanta Gozdzik, Zeynep Arzu Yeğin, Lucrecia Yañez, Luca Facchini, Gwendolyn Van Gorkom, Lorenz Thurner, Ulker Kocak, Antònia Sampol, Tsila Zuckerman, Marc Bierings, Stephan Mielke, Fabio Ciceri, Lotus Wendel, Nina Knelange, Malgorzata Mikulska, Dina Averbuch, Jan Styczynski, Rafael de la Camara, Simone Cesaro
BACKGROUND: Infections are the main reason for mortality during acute leukaemia treatment and invasive aspergillosis (IA) is a major concern. Allogeneic stem cell transplantation (alloSCT) is a standard therapy and often is the only live-saving procedure in leukaemia patients. The profound immunodeficiency occurring after alloSCT led to high IA-associated mortality in the past. Therefore, patients with IA were historically considered transplant-ineligible. Recently, there has been improvement of anti-fungal management including novel anti-fungal agents...
January 2024: EClinicalMedicine
keyword
keyword
163403
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.